Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells

Basit Öğe Kaydı
dc.authorscopusid55982152000
dc.authorscopusid55889548200
dc.authorscopusid57162951400
dc.authorscopusid6602877137
dc.authorscopusid6602989907
dc.contributor.authorSoylu, H.
dc.contributor.authorKırca, M.
dc.contributor.authorAvcı, S.
dc.contributor.authorOzpolat, B.
dc.contributor.authorUstunel, I.
dc.date.accessioned2021-12-01T18:38:54Z
dc.date.available2021-12-01T18:38:54Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractBackground: Prostate cancer is the most common cancer in men. A Notch signaling pathway is an important pathway in cell proliferation, differentiation, and fate. However, currently, the effects of abiraterone based-anti-androgene therapy and docetaxel, the most commonly used standard chemotherapy in prostate cancer treatment, on Notch signaling pathway are unknown. This study aimed to investigate the effects of abiraterone acetate and docetaxel on the expression of Notch1, Jagged1 and Hes1 in prostate cancer cell lines. Methods: In vitro effects of abiraterone acetate and docetaxel were examined on Notch1, Jagged1, and Hes1 expression in LNCaP and PC3 PCa cell lines by immunofluorescence, Western blot, and qRT-PCR. MTT proliferation assay was used to evaluate cell proliferation and survival. Results: We found that in the treatment of PC3 cells with abiraterone acetate, docetaxel, and their combination, only mRNA expressions of Notch1, Jagged1 and Hes1 were affected compared to control, but these expression differences were not observed in protein expression. In LNCaP cells, abiraterone acetate and the combination groups reduced Notch1 protein expression. All treatment groups did not alter Jagged1 expression compared to control, but significantly increased the Hes1 gene and protein expression. Conclusion: Our findings suggest that abiraterone and docetaxel treatments affects the expression of Notch signal pathway proteins. But these drugs especially cause significant upregulation in Hes1 expression in PCa cells. Therefore, co-application of Notch signaling inhibitors together with docetaxel and abiraterone chemotherapy, it was thought that decreased Hes1 expression could be stopped the deterioration of the prognosis of the patient. © 2021 Elsevier Inc.en_US
dc.description.sponsorshipAkdeniz Üniversitesi: TDK-2016-1395en_US
dc.description.sponsorshipThis work was supported by the Scientific Research Projects Coordination Unit of Akdeniz University (Project Number: TDK-2016-1395 ).en_US
dc.identifier.doi10.1016/j.yexmp.2021.104607
dc.identifier.issn00144800
dc.identifier.pmid33482170en_US
dc.identifier.scopus2-s2.0-85099812273en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1016/j.yexmp.2021.104607
dc.identifier.urihttps://hdl.handle.net/20.500.12684/9901
dc.identifier.volume119en_US
dc.identifier.wosWOS:000723248100007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Inc.en_US
dc.relation.ispartofExperimental and Molecular Pathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAbirateroneen_US
dc.subjectCanceren_US
dc.subjectDocetaxelen_US
dc.subjectNotchen_US
dc.subjectProstateen_US
dc.titleAntiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cellsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
9901.pdf
Boyut:
3.61 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu